banner
home azienda prodotti anatomia contatti
integratori
ombra_sx
red_line
down
icon
More info  
Diabetic retinopathy is the main cause of blindness between the ages of 20 and 70. Every year, 50,000 diabetic patients develop diabetic retinopathy in Italy alone.
This progressive and invalidating disease is certainly one of the most unfortunate complications of diabetes. In order to minimize the damage caused by this disease, it is important to take suitable preventive measures; diabetic patients must constantly check their glycemic index following the instructions of specialized centres. It is also very important to establish a support therapy which aims to help protect the retinal vascular system, the deterioration of which causes a series of complications which lead to increased deterioration of the patient’s vision which can end in blindness.
 
down
down
icon
Download  

Info in Vista 2006 N.1 RETINOPARIA DIABETICA

icon_pdf
Download the file (2,0 Mb)
 
down
down
icon_biblio
Bibliography

1) Funatsu H, Yamashita H.
Pathophysiology of Diabetic Retinopathy.
Drug News Perspect. 2002 Dec;15(10):633-639.

2. Kohner EM, Patel V, Rassam SM.
Role of blood flow and impaired autoregulation in the pathogenesis of diabetic retinopathy.
Diabetes. 1995 Jun;44(6):603-7. Review.

3. Wong TY, Klein R, Duncan BB, Nieto FJ, Klein BE, Couper DJ, Hubbard LD,
Sharrett AR.
Racial Differences in the Prevalence of Hypertensive Retinopathy.
Hypertension. 2003 Mar 24

4. Chatterjee S, Chattopadhyay S, Hope-Ross M, Lip PL, Chattopadhya S.
Hypertension and the eye: changing perspectives.
J Hum Hypertens. 2002 Oct;16(10):667-75. Review.

5. Hyman BN.
The Eye as a Target Organ: An Updated Classification of Hypertensive
Retinopathy. J Clin Hypertens (Greenwich). 2000 May;2(3):194-197.

6. Sayag D, Gotzamanis A, Brugniart C, Segal A, Ducasse A, Chambre V,
Glacet-Bernard A.
[Retinal vein occlusion and carotid Doppler imaging]
J Fr Ophtalmol. 2002 Oct;25(8):826-30. French.

7. Ueda Y, Kanazawa S, Ohira A, Miyamura N, Takaki T, Kitaoka T, Amemiya T.
Retinal vascular obstruction and asymptomatic cerebral infarction.
Jpn J Ophthalmol. 2002 Mar-Apr;46(2):209-14.

8. Recchia FM, Brown GC.
Systemic disorders associated with retinal vascular occlusion.
Curr Opin Ophthalmol. 2000 Dec;11(6):462-7. Review.

9. Bhagat N, Goldberg MF, Gascon P, Bell W, Haberman J, Zarbin MA.
Central retinal vein occlusion: review of management.
Eur J Ophthalmol. 1999 Jul-Sep;9(3):165-80. Review.

10. Wong VK.
Retinal venous occlusive disease.
Hawaii Med J. 1997 Oct;56(10):289-91. Review.

11. Laatikainen LT.
Management of retinal vein occlusion.
Curr Opin Ophthalmol. 1992 Jun;3(3):372-8. Review.

12. Glacet-Bernard A, Coscas G, Chabanel A, Zourdani A, Lelong F, Samama MM. A randomized, double-masked study on the treatment of retinal vein occlusion with troxerutin.
Am J Ophthalmol. 1994 Oct 15;118(4):421-9.

13. Agolini G, Cavallini GM.
[Long-term therapy of retinal vasculopathies with oral administration of high
doses of O-(beta-hydroxyethyl)-rutoside] Clin Ter. 1987 Jan 31;120(2):101-10.

14. Lumbroso Bruno
"Retinopatia Diabetica", pp 9-11, Casa Ed. ESAM Futura Roma, 1991. (modificata)

15. Incandela L, Cesarone MR, Cacchio M, De Sanctis MT, Santavenere C, D'Auro MG, Bucci M, Belcaro G.
Total triterpenic fraction of Centella asiatica in chronic venous insufficiency
and in high-perfusion microangiopathy.
Angiology. 2001 Oct; 52 Suppl 2:S9-13.

16. Cesarone MR, Incandela L, De Sanctis MT, Belcaro G, Bavera P, Bucci M, Ippolito E.
Evaluation of treatment of diabetic microangiopathy with total triterpenic
fraction of Centella asiatica: a clinical prospective randomized trial with a
microcirculatory model.
Angiology. 2001 Oct;52 Suppl 2:S49-54.

17. Cesarone MR, Incandela L, De Sanctis MT, Belcaro G, Geroulakos G, Griffin M, Lennox A, Di Renzo AD, Cacchio M, Bucci M.
Flight microangiopathy in medium- to long-distance flights: prevention of edema and microcirculation alterations with total triterpenic fraction of Centella asiatica. Angiology. 2001 Oct;52 Suppl 2:S33-7.

18. Cesarone MR, Laurora G, De Sanctis MT, Incandela L, Grimaldi R, Marelli C,
Belcaro G.
[The microcirculatory activity of Centella asiatica in venous insufficiency. A double-blind study] Minerva Cardioangiol. 1994 Jun;42(6):299-304. Italian.

19. Cesarone MR, Laurora G, De Sanctis MT, Belcaro G.
[Activity of Centella asiatica in venous insufficiency] Minerva Cardioangiol. 1992 Apr;40(4):137-43. Italian.

20. Belcaro GV, Grimaldi R, Guidi G.
Improvement of capillary permeability in patients with venous hypertension
after treatment with TTFCA. Angiology. 1990 Jul;41(7):533-40.

21. Droy-Lefaix MT, Cluzel J, Menerath JM, Bonhomme B, Doly M.
Antioxidant effect of a Ginkgo biloba extract (EGb 761) on the retina.
Int J Tissue React. 1995;17(3):93-100.

22. Ellnain-Wojtaszek M, Kruczynski Z, Kasprzak J.
Investigation of the free radical scavenging activity of Ginkgo biloba L. leaves.
Fitoterapia. 2003 Feb;74(1-2):1-6.

23. Koltringer P, Langsteger W, Klima G, Reisecker F, Eber O.
[Hemorheologic effects of ginkgo biloba extract EGb 761. Dose-dependent effect of EGb 761 on microcirculation and viscoelasticity of blood]
Fortschr Med. 1993 Apr 10;111(10):170-2. German.

24. Shen L, Cui Y.
[Effects of the leaf of Ginkgo biloba L. extract on blood rheology in animals]
Zhongguo Zhong Yao Za Zhi. 1998 Oct;23(10):622-3, 640- inside back cover.

25. Pepe C, Rozza A, Veronesi G.
[The evaluation by video capillaroscopy of the efficacy of a Ginkgo biloba
extract with L-arginine and magnesium in the treatment of trophic lesions in
patients with stage-IV chronic obliterating arteriopathy] Minerva Cardioangiol. 1999 Jun; 47(6):223-30. Italian.

26. Lotz-Winter H.
On the pharmacology of bromelain: an update with special regard to animal
studies on dose-dependent effects. Planta Med. 1990 Jun;56(3):249-53. Review.

27. Taussig SJ, Yokoyama MM, Chinen A, Onari K, Yamakido M.
Bromelain: a proteolytic enzyme and its clinical application. A review.
Hiroshima J Med Sci. 1975 Sep;24(2-3):185-93. Review.

28. Erdinçler, D. S., Karakoç, Y et al
The effect of Ginkgo biloba glycoside on the blood viscosity and erythrocyte deformability.
Clinical Hemorheology 1996, Vol. 16, No. 3, pp. 271-276.

29. Venditti P, Masullo P, Di Meo S, Agnisola C.
Protection against ischemia-reperfusion induced oxidative stress by vitamin E
treatment. Arch Physiol Biochem. 1999 Feb;107(1):27-34.

30. Rose RC, Bode AM.
Biology of free radical scavengers: an evaluation of ascorbate.
FASEB J. 1993 Sep;7(12):1135-42. Review.

31. Retsky KL, Freeman MW, Frei B.
Ascorbic acid oxidation product(s) protect human low density lipoprotein
against atherogenic modification. Anti- rather than prooxidant activity of
vitamin C in the presence of transition metal ions.
J Biol Chem. 1993 Jan 15;268(2):1304-9.

32. Yasuo Oyama, Paul A. Fuchs et al.
Myricetin and quercetin, the flavonoid constituents of Ginkgo biloba extract, greatly reduce oxidative metabolism in both resting and Ca++-loaded brain neurons.
Brain Research 635 (1994) 125-129.

33. Schonlau F, Rohdewald P.
Pycnogenol for diabetic retinopathy. A review.
Int Ophthalmol. 2001;24 (3): 161-71.

34. Spadea L, Balestrazzi E.
Treatment of vascular retinopathies with Pycnogenol.
Phytother Res. 2001 May;15 (3): 219-23.

35. Packer L, Rimbach G, Virgili F.
Antioxidant activity and biologic properties of a procyanidin-rich extract from pine (Pinus maritima) bark, pycnogenol.
Free Radic Biol Med. 1999 Sep;27 (5-6): 704-24.

36. Rohdewald P.
Review: The French maritime pine bark extract (Pycnogenol).
Int J Clin Pharm Ther. 2002 (40): 158-168.

37. Cho KJ, Jun CH et al.
Inhibition mechanisms of bioflavonoids extracted from the bark of pinus maritima on the expression of proinflammatory cytokines.
Ann NY Acad Sci. 2001 (928): 141-156.

 
down
 
maxiven cromo
Composition
 
>> Red Capsule (MORNING)
CHROMIUM 0,02 mg
RESVERATROL 10 mg
OMEGA 3 400 mg
GINGKO BILOBA 60 mg
 
>> GRENN Capsule (NIGHT)
CHROMIUM 0,02 mg
OMEGA 3 220 mg
GINGKO BILOBA 60 mg
RUTIN 30 mg
EXTRACT OF BISHOP PINE BARK 50 mg
VITAMIN E 12 mg
VITAMIN C 80 mg
VITAMINE FROM THE B GROUP (B3 16 mg - B9 0,2 mg
B6 1,4 mg - B12 0,0025 mg)
 
Description

Food Supplement of vitamins, chromium and plant extracts in fish oil

MAXIVEN® cromo is a product composed of a rational association of all natural components that exert vascoprotective, hemorheologic, anti-edemigenous and antioxidant action.

 

Diabetic retinopathy is the main cause of blindness between the ages of 20 and 70.

grafico

Every year, 50,000 diabetic patients develop diabetic retinopathy in Italy.

GINKGO BILOBA - Vasoregulatory and hemorheologic action.
Helps keep blood values within normal levels and favors the speed of the haematic flux.

Chromium is an important trace element for the human body given that lack of this metal leads to imbalances in the metabolization of glucose, fats and protein that manifest through hyperglycemia, obesity, decreased tissue sensitivity to insulin, tendency towards arteriosclerosis and reduced resistance to infections.

Despite the fact that chromium is available in nature in many foods (calf liver, fresh fruit, dairy goods, beef, oysters, fowl) it is difficult to properly assimilate it due to the excessive processing of foodstuffs. Clinical research performed in the last years has widely proven that chromium fosters the metabolization of glucose, cooperation with insulin in regulating glycemia levels, insulin requirements, and improves glucose tolerance in many subjects contracting late onset diabetes.

Studies conducted on patients affected by diabetes show:
a)A remarkable decrease (almost reaching normalization) of blood glucose levels;
b)Decrease on insulin levels and cholesterol;
c)Improvement in the normalization of the glycemic index in the two post hours of administration

Extract of Ginkgo Biloba is a precious source of active biological compounds whose properties are widely exploited in many fields of application. The effect induced by this extract is obtained through the synergic action of its constituting components.
The terpenoids and flavonoids, with different mechanisms of action but having synergic effects, help maintain blood fluidity levels within normal ranges and, in such manner, foster the haematic flux in the small blood vessels.
The extract of Ginkgo biloba also seems able to increase the speed on the ocular haematic flow. In addition, various studies have highlighted a neuroprotective effect.

The extracts of Ginkgo biloba, Vitamin E, Vitamin C, neutralizing free radicals, are recognized as active antioxidant elements able to protect the integrity of the vessel and tissue structures from damage attributed to oxidation (antioxidant effect).
The extract of Bishop Pine contains numerous substances, Oligomeric proanthocyanidins, which have proved extremely active in protecting small blood vessel walls by increasing tone and resistance. The Oligomeric proanthocyanidins contribute in establishing a normalization of capillary permeability and protect collagen integrity that is part of the vessel wall (vasoprotective effect). The extracts contained in the bark of bishop pine also reduce damage due to oxidation inflicted by free radicals on cellular membranes and DNA, also protecting cells from lipid peroxidation.

Rutin, equal to its derivates, exerts a protective action on the small vessels, both at the endothelial areas and on the perivesical fascia. In fact, it improves the functionality of the endothelial cells and stimulates fibrinolytic activity.

The benefits of omega 3 (fish oil, EPA and DHA) for patients with insulin resistance or full-blown diabetes were hypothesized on the grounds of the first epidermiologic studies, which have shown a reduction in pathology prevalence in the range of populous that consumes great quantities of polyunsaturated fatty acids of omega 3 origin.

Even healthy individuals benefit by introducing fish oil in their diets through reduced insulinic response to intake of glucose. Enhancing diets with omega 3 also leads to decrease glucose oxidation, greater lipid oxidation and deposit of glycogen, without any modification of the glycemic response, only improving sensitivity to insulin. It has been hypothesized that fish omega 3 represents an efficient nutritional instrument in preventing and decreasing muscle insulin resistance associated with obesity.
The retina contains a rich source of long-chain fatty acids. The DHA can constitute up to 50% of the composition of fatty acids of the phospholipids of this tissue – fact that suggests its potential and probable involvement in visual functions. Indeed, sight would be impossible without the presence of DHA.

Resveratrol is a potent natural antioxidant that mostly comes from grape skin. In nature, resveratrol acts as protective agent for plants against infections, fungal attacks, and attacks from harsh agents, such as parasites, toxic environmental substances and UV rays. It acts as an anti-inflammatory agent in the human body, also serving as cell protector with great benefit for blood vessels, the heart and liver/brain cells.

The Vitamins of the B group are deemed a valid contribution in controlling the level of homocisteina in the blood. These vitamins also prove particularly helpful in preventing the risk of occlusion of the veins and arteries of the retina. In addition, it is hypothesized that these vitamins exert a direct anti-oxidant action.

 
Product Use

INDICATIONS
MAXIVEN® cromo perfect in cases of increased need or reduced intake of nutrients MAXIVEN® cromo can prove particularly useful in facilitating microcirculation during increased capillary fragility and permeability, in presence vascular edema or to increase the body’s defense system against oxidation caused by free radicals.
This is a frequent situation during vascular retinopathy such as, for example, diabetic retinopathy and venal thrombosis.

DOSAGE AND ADMINISTRATION
2 capsules/day: red in the morning and green at night. Swallow with water and take independently from meals.

PACKAGE
The package contains two blister packs with 20 tablets each.

 
 
flaguk end